Search results
Results from the WOW.Com Content Network
The US Food and Drug Administration (FDA) approved durvalumab for certain types of bladder, lung, and biliary tract cancer: [6] [13] [14]. Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum ...
Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after chemoradiation. [ 33 ] Cosibelimab (Unloxcyt) by Checkpoint Therapeutics is a PD-L1 inhibitor developed by Dana Farber, and was approved in the United States in December 2024 for cutaneous squamous cell carcinoma .
Tremelimumab is indicated, in combination with durvalumab, for the treatment of adults with unresectable hepatocellular carcinoma. [7] [11] [8]Tremelimumab in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer with no sensitizing epidermal growth factor receptor mutations or anaplastic ...
Quantum Leap Healthcare Collaborative Announces Completion of Datopotamab Deruxtecan and Datopotamab Deruxtecan + Durvalumab Arms in the I-SPY2 Trial for Stage 2/3 Neoadjuvant Breast Cancer San Francisco, CA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor and operator of the I-SPY 2 Trial, announces ...
Here are links to possibly useful sources of information about Durvalumab. PubMed provides review articles from the past five years (limit to free review articles) The TRIP database provides clinical publications about evidence-based medicine. Other potential sources include: Centre for Reviews and Dissemination and CDC
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a ...
Health officials in Europe are investigating Ozempic and the trendy drug’s possible link to an eye-rotting condition that causes blindness. On Dec. 17, the European Medicines Agency announced ...
Judy Rodriguez was 30 when her family reported her missing on January 23, 1991, a short time after her daughter Stephanie’s first birthday party.